000			nab a22 7a 4500
999			_c17011 _d17011
003			PC17011
005			20221013113431.0
008			221013b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_9432 _aManso Sánchez, Luis _eOncología Médica
100			_91181 _aCortés-Funes Castro, Hernán _eOncología Médica
100			_9431 _aGrávalos Castro, Cristina _eOncología Médica
245	0	0	_aFactors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study. _h[artículo]
260			_bAnticancer research, _c2015
300			_a35(12):6941-50.
500			_aFormato Vancouver: Manso L, Palomo AG, Pérez Carrión R, Cassinello J, Gallegos Sancho I, Chacón López-Muñiz I et al. Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study. Anticancer Res. 2015 Dec;35(12):6941-50.
501			_aPMID: 26637920
504			_aContiene 24 referencias
520			_aAim: To evaluate factors associated with the selection of first-line bevacizumab plus chemotherapy and clinical response in HER2-negative metastatic breast cancer (MBC) in clinical practice in Spain. Patients and methods: All consecutive adult female patients with HER2-negative MBC who had received first-line bevacizumab plus chemotherapy for at least 3 months were enrolled in the present study. Results: A total of 292 evaluable patients were included; 25% had triple-negative breast cancer (TNBC) and 75% had hormone receptor-positive breast cancer (HRPBC). Nearly 40% of patients had ≥3 metastatic sites, mainly located in the bone (48%) and liver (40%). Bevacizumab was mostly combined with paclitaxel (67.1%). ER-positive tumors were only identified as an independent factor associated with the choice of treatment (odds ratio (OR): 0.538; p=0.02). The overall response rate (ORR) was 63.7% (TNBC: 57.5%; HRPBC: 65.9%). Patients aged 36-50 years (OR: 3.03; p=0.028) and those with metastases at sites other than the bone (OR: 0.38; p=0.001) and ≥3 metastatic sites (OR: 1.41; p=0.018) were more likely to achieve objective responses. Conclusion: First-line bevacizumab plus chemotherapy, mainly paclitaxel, is an effective and well-tolerated treatment option for HER2-negative MBC, particularly in more aggressive disease.
710			_9303 _aServicio de Oncología Médica
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc17011.pdf _ySolicitar documento
942			_2ddc _cART _n0